Voyager Therapeutics is a biotechnology company developing genetic medicines and neurotherapeutics for neurological diseases, with a primary focus on Alzheimer’s disease. The company’s pipeline includes VY1706, a tau silencing gene therapy, and VY7523, an anti-tau antibody, both targeting Alzheimer’s disease. Voyager utilizes its proprietary TRACER platform to discover adeno-associated virus capsids that enable intravenous delivery across the blood-brain barrier, and the Voyager NeuroShuttle platform for non-viral delivery of neurotherapeutics. The company collaborates with partners including Neurocrine Biosciences, Novartis, Alexion, and Transition Bio on programs for Friedreich’s ataxia, Parkinson’s disease, Gaucher disease, spinal muscular atrophy, Huntington’s disease, and amyotrophic lateral sclerosis. These partnerships involve gene therapies and small molecule programs, with Voyager retaining options to co-develop and co-commercialize certain assets. The company’s therapeutic areas include diseases of the central nervous system, leveraging human genetics to modify disease progression.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage voyagertherapeutics.com
Sector Healthcare IR page ir.voyagertherapeutics.com
Tags
gene therapy, neurological diseases, alzheimer's disease, blood-brain barrier delivery, aaav capsids, tau protein, friedreich's ataxia, parkinson's disease, amyotrophic lateral sclerosis, monoclonal antibodies, VY1706, VY7523, TRACER, Voyager NeuroShuttle, ALPL-VYGR-NeuroShuttle, NBIB-’223, Neurocrine, Novartis, Alexion, Transition Bio
Press page —

Metrics

Valuation  
Market cap $ 166.625M
Market cap (USD) $ 166.625M
P/E -1.54
PEG —
P/BV 1.23
P/S 6.64
P/OCF -1.53
P/FCF -1.52
Dividend yield —
Turnover / mcap —
Returns  
ROE -48.3%
ROI -75.1%
ROIC -62.0%
Profit margin -296.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -83.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 40.374M 80.001M 250.008M 40.907M 37.415M 171.128M 104.391M 7.619M 10.135M 14.22M 17.334M —
Net profit -119.721M -65.002M 132.33M -46.408M -71.197M 36.741M -43.597M -88.288M -70.698M -40.193M -29.672M -16.317M
Free cash flow -135.063M -18.831M 74.663M -15M -55.134M -108.813M 40.948M -20.192M -65.335M -47.511M 40.269M -14.906M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 3.93 5.67 8.44 6.1 2.71 7.15 13.95 9.4 16.6 12.74 21.9 —
Price performance 12m -0.31 -0.33 0.38 1.25 -0.62 -0.49 0.48 -0.43 0.3 -0.42 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — — — — 80.2M 1.5M 1.76M
↳ YoY growth -98.1% +17.1%
Lease liabilities (USD) — — — 34.2M 47.6M 44.2M 23.1M 20.3M 43.7M 36.5M
Cash and deposits (USD) 36.6M 31.5M 46.9M 86M 104M 117M 99M 68.8M 71.4M 65.3M
Right-of-use assets (USD) — — — 28.5M 36.1M 33.5M 15.5M 13.5M 33.3M 28.5M
Cash flow detail
Operating cash flow (USD) -42.5M -61.4M -15.9M 48.7M -96.7M -53.5M -12.5M 77.9M -15.3M -132M
Purchases of property, plant and equipment (USD) -5.03M -3.99M -4.31M -7.72M -12.1M -1.61M -2.49M -3.26M -3.52M -2.6M
Change in receivables (cash effect) (USD) — — — — — — — -80.2M 78.6M -257,000
Change in payables (cash effect) (USD) -62,000 470,000 -282,000 2.6M -3.44M -60,000 1.99M -962,000 2.39M 1.02M
Income taxes paid (cash effect) (USD) — — — — — — — -16,000 -1.48M -714,000
Share-based compensation (USD) 6.31M 9.24M 15.7M 15.6M 14.9M 11.3M 9.34M 11.2M 14.8M 14.8M
Operating cash flow before change in receivables (USD) — — — — — — — 158M -94M -132M
Free cash flow (OCF - PPE - intangibles) (USD) -47.5M -65.3M -20.2M 40.9M -109M -55.1M -15M 74.7M -18.8M -135M
Income detail
Research and development expense (USD) 42.2M 62.3M 64.9M 120M 109M 73.8M 60.8M 92.2M 127M 135M
↳ 5y CAGR +68.2% +31.5% +11.8% -0.5% +7.3% +1.2% +4.4%
Total comprehensive income (USD) -40M -70.9M -88.3M -43.6M 36.7M -71.2M -46.5M 133M -65.4M -119M
Comprehensive income to owners (USD) -40M -70.9M -88.3M -43.6M 36.7M -71.2M -46.5M 133M -65.4M -119M
Reported Mar 15, 2017 Mar 14, 2018 Feb 26, 2019 Mar 3, 2020 Feb 25, 2021 Mar 8, 2022 Mar 7, 2023 Mar 9, 2026 Mar 9, 2026 Mar 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -

- Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months -

- Ended Q3 2026 with cash position of $132 million, runway into Q2 2028 -

LEXINGTON, Mass., November 5, 2026 — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2026 financial and operating results.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028.

11/05/26

PDF Version

  • VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -

  • Neurocrine Biosciences partnered Friedreich’s ataxia gene therapy program expected to enter the clinic in the coming months -

  • Ended Q3 2026 with cash position of $132 million, runway into Q2 2028 -

LEXINGTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported third quarter 2026 financial and operating results.

“There is strong momentum behind our two tau-targeted Alzheimer’s disease programs, and we expect to report PET imaging data from our VY7523 multiple ascending dose trial in the fourth quarter and to dose the first patient with our lead gene therapy VY1706 in the next few months,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “During the third quarter, we continued to be disciplined in our operations to reduce year-over-year operating expenses and as a result, we have extended our cash runway into the second quarter of 2028. This strengthens our position as we approach key upcoming milestones.”

Third Quarter 2026 and Recent Business Highlights

  • **VY7523 (anti-tau antibody):**The last patient visit is complete, and Voyager continues to expect tau positron emission tomography (PET) imaging efficacy data in Q4 2026 from the multiple ascending dose (MAD) clinical trial in participants with Alzheimer’s disease (AD).

  • **VY1706 (tau silencing gene therapy):**Patient screening continues in the United States for the clinical trial in adults with early AD, and, pending enrollment, Voyager expects patient dosing to begin in the next few months, initial acute safety data in the first quarter of 2027, and the potential to establish capsid platform validation with initial CSF tau biomarker-based data approximately one year after dosing begins.

  • **Presentation at ESGCT 2026:**Voyager presented a pharmacology and safety summary from its 6-month good laboratory practice (GLP) toxicology non-human primate (NHP) study of VY1706.

  • **NBIB-‘223 (Friedreich’s ataxia gene therapy):**Voyager’s partner, Neurocrine Biosciences, said that the program is expected to enter a Phase 1 clinical study in the coming months, with initial patient-level data anticipated in 2027.

  • Robin Swartz appointed as President: As announced in October 2026, as part of a planned leadership transition, Swartz was appointed President and is expected to succeed current CEO Dr. Sandrock**.**

Upcoming Presentations

  • Guggenheim 3rd Annual Healthcare Innovation Conference, November 9, 2026: fireside chat and participating in one-on-ones.

  • Stifel 2026 Healthcare Conference, November 10, 2026: fireside chat at 2:00 p.m. ET and participating in one-on-ones. A webcast of the fireside chat will be available and may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com. A replay will be archived on Voyager’s website for at least 30 days.

  • 19thClinical Trials on Alzheimer's Disease (CTAD) Conference, November 16-19, 2026: poster presentations summarizing the baseline characteristics of patients enrolled in the VY7523 MAD clinical study and the design of the first-in-human study for VY1706.

  • Antibody Engineering & Therapeutics US 2026 Conference, December 13-16, 2026: poster presentation on the Voyager NeuroShuttle™ platform including identification and characterization of ALPL antibodies and in vivo PK in mice and non-human primates.

Third Quarter 2026 Financial Results

  • Collaboration Revenues: Collaboration revenue was $4.0 million for the third quarter of 2026, compared to $13.4 million for the third quarter of 2025. The decrease was primarily attributable to lower revenue recognized under the Neurocrine collaboration agreement as activities transition beyond the research phase.

  • Research and Development Expenses: Research and development expenses were $24.4 million for the third quarter of 2026, compared to $35.9 million for the third quarter of 2025. The decrease was primarily attributable to lower clinical and manufacturing costs and program prioritization.

  • General and Administrative Expenses: General and administrative expenses were $6.1 million for the third quarter of 2026, compared to $8.1 million for the third quarter of 2025. The decrease was primarily attributable to lower employee-related expenses and consulting costs.

  • Net Loss: Net loss was $24.7 million for the third quarter of 2026, compared to $27.9 million for the third quarter of 2025.

  • Cash and Cash Equivalents and Marketable Securities: Cash, cash equivalents, and marketable securities as of September 30, 2026, were $132.1 million. Based on Voyager’s current operating plans, the company expects its cash, cash equivalents, and marketable securities, together with anticipated collaboration reimbursements and interest income, to be sufficient to fund planned operating expenses and capital expenditures into the second quarter of 2028.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws about Voyager’s belief, expectations, plans and prospects regarding the development, regulatory status of its product candidates and advancement of its preclinical and clinical development programs, including Voyager’s advancement of the tau silencing gene therapy program in AD, VY1706, and the expected timing of enrollment, dosing and initial acute safety data, and initial biomarker-based data; the progress and timing of Voyager’s clinical-stage anti-tau antibody program in AD, VY7523, including the timing of expected clinical tau PET imaging efficacy data and other clinical data; Voyager’s ability to advance gene therapy product candidates under the Novartis licenses and collaboration and Neurocrine collaboration, including the anticipated progression into the clinic by Neurocrine for NBIB-‘223 in FA; the role of tau in the treatment of AD, including as a critical disease-modifying target; the therapeutic potential, safety, and pharmacological effect of Voyager’s current and future product candidates; Voyager’s anticipated financial results, including the anticipated receipt by Voyager of revenues or reimbursement payments from collaboration partners; Voyager’s cash runway, anticipated cost savings, including as a result of cost-cutting and efficiency initiatives, and its ability to execute across its pipeline and platforms; the mission, goals and value drivers for Voyager’s business; Voyager’s expected succession plan; Voyager’s anticipated presentation at upcoming events and conferences; and the ability to generate sufficient cash resources to enable Voyager to continue its business and operations through multiple clinical inflection points. The use of words such as “may,” “will,” “might,” “would,” “could,” “should,” “expect,” “plan,” “anticipate,” “believe,” “view,” “potential,” “intend,” “seek,” “predict,” “estimate,” “project,” “target,” or “continue” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

All forward-looking statements are based on management’s current estimates and assumptions and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from any forward-looking statements in this press release. Factors include, among others, the risks and uncertainties inherent in the development of product candidates, including the timing, initiation, and conduct of preclinical studies and clinical trials, including potential delays in timing as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials, conduct additional pre-clinical studies, or other changes, which may impact Voyager’s ability to meet its expected timelines and may increase its costs; the expectations and decisions of regulatory authorities; the availability of data from and outcomes of Voyager’s preclinical studies and clinical trials and those conducted by its partners and collaborators, including that success in earlier preclinical studies may not be repeated or observed in ongoing or future preclinical studies or clinical trials, ongoing and future clinical trials may not meet their primary or key secondary endpoints, which may substantially impair development, timing for expected data may be delayed, and Voyager may encounter adverse events that could negatively impact further development; Voyager’s ability to demonstrate that current or future product candidates are safe and effective for their proposed indications; the availability, commercial potential and success of Voyager’s wholly owned candidates; the availability of data from and the outcomes of third-party preclinical studies and clinical trials and the potential impact on Voyager’s development plans; the continued development of Voyager’s technology platforms, including Voyager’s TRACER and nonviral discovery platforms; Voyager’s scientific approach and program development progress and the restricted supply and increased costs of critical research components; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid and nonviral discovery platform and programs; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid and nonviral discovery platforms, the capsids and ligands identified by the platforms, and the development of clinical candidates and related data from Voyager’s pipeline programs; the willingness and ability of Voyager's collaboration partners to meet obligations under collaboration agreements with Voyager and their projections with respect to such programs; the need to align with its collaborators, which may hamper or delay its development efforts and timelines; the possibility or timing of Voyager’s receipt of program reimbursement, development or commercialization milestone payments, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the success of programs controlled by third-party collaboration partners in which Voyager retains a financial interest, including that the anticipated benefits of these ongoing collaborations, including the receipt of payments or the successful development or commercialization of products and generation of revenue, may never be achieved at the levels or timing Voyager expects or at all; the adverse impact on Voyager’s business if any of its key collaborators fails to perform its obligations or terminates the collaboration; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; additional funding may not be available on acceptable terms when needed, or at all, which could hamper Voyager’s development efforts; the ability to attract and retain talented directors, employees, and contractors and the resulting impact to Voyager’s business and ability to meet its goals and timelines; the sufficiency of Voyager’s cash resources to fund its operations and pursue its corporate objectives; any of the foregoing events could impair the drivers and value creation opportunities for Voyager’s business; and technical and other unexpected hurdles in the development, manufacture and supply of product candidates, may delay Voyager’s timing, change its plans, increase its costs, or otherwise negatively impact its business.

These risks and uncertainties are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

10/27/26

PDF Version

LEXINGTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager’s investigational gene therapy designed to lower tau production in the brain, and VY7523, the Company’s clinical stage monoclonal antibody directed against the C-terminal region of tau.

CLINICAL TRIALS – PHASE I & IIA First-in-human study design of VY1706, a systemically administered blood-brain barrier (BBB)-penetrant tau lowering gene therapy in early Alzheimer’s disease (#P055). Elena Ratti, M.D., MMSc, VP, Clinical Development. Monday, November 16, 2026, 2:00 p.m. - Tuesday, November 17, 2026, 5:30 p.m. ET

Baseline characteristics of participants enrolled in a multiple ascending dose study of the C-terminal targeting anti-tau antibody VY7523 in early Alzheimer’s disease (#P054). Elena Ratti, M.D., MMSc, VP, Clinical Development. Monday, November 16, 2026, 2:00 p.m. - Tuesday, November 17, 2026, 5:30 p.m. ET

The poster presentations will be available on Voyager’s website at: https://www.voyagertherapeutics.com/science-publications.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit http://www.voyagertherapeutics.com.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, without limitation, implied and express statements about Voyager’s belief and expectations regarding the development of its product candidates and advancement of its preclinical and clinical development programs, including Voyager’s advancement of the tau silencing gene therapy program in AD, VY1706, including the first-in human study design of VY1706 and timing of achievement of clinical development milestones for VY1706, including initiation of clinical trials and achievement of first-in-human dosing in AD. Voyager’s ability to advance its clinical-stage anti-tau antibody program in AD, VY7523; the therapeutic potential, safety, and pharmacological effect of Voyager’s current and future product candidates; the mission, goals and value drivers for Voyager’s business; and the ability to generate sufficient cash resources to enable Voyager to continue its business and operations through multiple clinical inflection points. The use of words such as “may,” “will,” “might,” “would,” “could,” “should,” “expect,” “plan,” “anticipate,” “believe,” “view,” “potential,” “intend,” “seek,” “predict,” “estimate,” “project,” “target,” or “continue” and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

All forward-looking statements are based on management’s current estimates and assumptions and are subject to a number of risks, uncertainties and important factors that may cause actual results to differ materially from any forward-looking statements in this press release. Factors include, among others, the risks and uncertainties inherent in the development of product candidates, including the initiation, timing, cost, progress, and results of Voyager’s planned and future clinical trials including potential delays in timing as a result of slower than expected site initiation, slower than expected enrollment, the need or decision to expand the trials or other changes, which may impact Voyager’s ability to meet its expected timelines and may increase its costs; expectations and decisions of regulatory authorities; Voyager’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; potential adverse events Voyager may encounter that could negatively impact development; Voyager’s ability to demonstrate that current or future product candidates are safe and effective for their proposed indications; Voyager’s scientific approach and continued development of our technology platforms, including the TRACER and non-viral discovery platforms; the development by third parties of capsid identification platforms that may be competitive to our platforms and programs; Voyager’s ability to create and protect our intellectual property rights; the progress and success of programs under current or future collaboration and license agreements; the sufficiency of Voyager’s cash resources to fund our operations and pursue our corporate objectives; technical and other unexpected hurdles in the development, manufacture and supply of our product candidates, may delay our timing, change our plans, increase our costs, or otherwise negatively impact our business; the ability to attract and retain talented directors, employees, and contractors and the resulting impact to Voyager’s business and ability to meet its goals and timelines; any of the foregoing events could impair the drivers and value creation opportunities for Voyager’s business.

These risks and uncertainties are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Prompts

Voyager Therapeutics, Inc. (ticker VYGR), listed in United States.

ETFs Holding Voyager Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.01% 119,678 $ 195.075K Nov 16, 2026
FESM 0.01% 138,411 $ 484.439K Jun 30, 2026
DFAS 0.00% 285,611 $ 485.539K Nov 12, 2026
DXUV 0.00% 32,823 $ 55.799K Nov 12, 2026
DFSU 0.00% 4,268 $ 7,255.60 Nov 12, 2026
DFAC 0.00% 39,859 $ 67.76K Nov 12, 2026
DCOR 0.00% 6,400 $ 10.88K Nov 12, 2026
AVUS 0.00% 22,313 $ 36.37K Nov 16, 2026